TDOC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Teladoc Health Inc (TDOC) is not a strong buy for a beginner investor with a long-term strategy at this time. The company is facing significant challenges, including declining revenue and earnings, as well as gross margin pressure. While there are some positive catalysts, such as an upgrade from BofA and better-than-expected Q4 results, the overall sentiment from analysts and financial performance trends suggest caution. The technical indicators and options data also do not strongly support an immediate buy decision.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a downward trend. The stock is currently trading near its resistance level (R1: 5.281), which may limit upside potential in the short term.
BofA upgraded the stock to Buy, citing confidence in margin improvements at BetterHelp.
Q4 2025 revenue exceeded expectations, driven by international growth.
AI Stock Picker and SwingMax signals are neutral, avoiding any immediate sell signals.
Analysts have broadly lowered price targets, with concerns about declining revenue, EBITDA, and gross margins.
U.S. revenue is under pressure, and the company is struggling to evolve its value proposition in a commoditized market.
Financial performance shows declining net income (-48.06% YoY) and EPS (-50.00% YoY).
In Q4 2025, revenue increased slightly by 0.28% YoY to $642.27 million, but net income dropped significantly by -48.06% YoY to -$25.14 million. EPS fell by -50.00% YoY to -$0.14, and gross margin declined by -3.50% YoY to 54.55%. These trends indicate financial struggles and limited growth.
Analyst sentiment is mixed but leans negative. Several firms, including Stifel, Evercore ISI, and Piper Sandler, have lowered price targets, citing challenges in the company's business model and market conditions. However, BofA and Goldman Sachs maintain Buy ratings, highlighting potential in margin improvements and international growth.
